Trastuzumab in metastatic breast cancer

Metastatic breast cancer is an incurable disease in a very high percentage of patients. Despite new progress in endocrine and other systemic therapies, this evidence remains challenging for patients and clinicians. HER2 protein is a member of the epidermal growth factor family of transmembrane recep...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of gynaecological oncology Vol. 27; no. 3; p. 247
Main Authors Tomao, F, Miele, E, Spinelli, G P, Russillo, M, La Ferla, G, Tomao, S
Format Journal Article
LanguageEnglish
Published Italy 2006
Subjects
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Female
Humans
Neoplasm Metastasis
Receptor, ErbB-2 - metabolism
Trastuzumab
Online AccessGet more information

Cover

More Information
Summary:Metastatic breast cancer is an incurable disease in a very high percentage of patients. Despite new progress in endocrine and other systemic therapies, this evidence remains challenging for patients and clinicians. HER2 protein is a member of the epidermal growth factor family of transmembrane receptors. HER2 is overexpressed in approximately 20% to 30% of breast cancers. Overexpression of HER2 has been shown to be associated with increased tumor proliferation and relative resistance to some types of chemotherapy and hormonal therapies. Trastuzumab, a humanized monoclonal antibody directed against HER2 protein, has been shown to be an efficacious and well tolerated treatment for HER2-overexpressing metastatic breast cancer, both as a single agent and when it is used in combination with chemotherapy.
ISSN:0392-2936